| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Migraine with Aura | 3 | 2019 | 33 | 2.27 | Why? |
| Migraine Disorders | 11 | 2020 | 530 | 2.16 | Why? |
| Amyotrophic Lateral Sclerosis | 10 | 2019 | 398 | 1.86 | Why? |
| Functional Neuroimaging | 4 | 2019 | 86 | 1.77 | Why? |
| Nerve Net | 5 | 2019 | 118 | 1.63 | Why? |
| Connectome | 4 | 2019 | 67 | 1.20 | Why? |
| Multiple Sclerosis | 14 | 2021 | 2600 | 1.19 | Why? |
| Neural Pathways | 5 | 2019 | 155 | 1.11 | Why? |
| Neurology | 8 | 2021 | 1613 | 0.98 | Why? |
| Visual Pathways | 2 | 2019 | 21 | 0.95 | Why? |
| Pain Perception | 2 | 2018 | 48 | 0.91 | Why? |
| Brain | 9 | 2018 | 5133 | 0.87 | Why? |
| Parkinson Disease | 7 | 2020 | 1414 | 0.86 | Why? |
| Magnetic Resonance Imaging | 16 | 2019 | 6551 | 0.82 | Why? |
| Trigeminal Nuclei | 1 | 2019 | 2 | 0.82 | Why? |
| Visual Cortex | 1 | 2019 | 12 | 0.80 | Why? |
| Cerebellum | 2 | 2019 | 119 | 0.75 | Why? |
| Migraine without Aura | 1 | 2018 | 14 | 0.74 | Why? |
| Pain Threshold | 1 | 2018 | 46 | 0.73 | Why? |
| Frontotemporal Lobar Degeneration | 1 | 2017 | 20 | 0.71 | Why? |
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2017 | 19 | 0.71 | Why? |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2018 | 40 | 0.70 | Why? |
| Central Nervous System Agents | 1 | 2017 | 45 | 0.67 | Why? |
| Fructose | 1 | 2017 | 52 | 0.67 | Why? |
| Memory Disorders | 1 | 2018 | 190 | 0.63 | Why? |
| Neural Conduction | 1 | 2018 | 261 | 0.62 | Why? |
| Pain | 3 | 2019 | 1084 | 0.61 | Why? |
| Neuropsychological Tests | 7 | 2018 | 954 | 0.61 | Why? |
| Meningitis | 1 | 2017 | 163 | 0.58 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 5 | 2020 | 529 | 0.57 | Why? |
| Immunoglobulins | 1 | 2018 | 811 | 0.47 | Why? |
| Headache | 2 | 2018 | 2257 | 0.40 | Why? |
| Apathy | 3 | 2019 | 35 | 0.40 | Why? |
| Neurophysiology | 2 | 2020 | 86 | 0.38 | Why? |
| Cognitive Reserve | 2 | 2018 | 17 | 0.38 | Why? |
| Magnetoencephalography | 2 | 2018 | 29 | 0.37 | Why? |
| Thalamus | 2 | 2019 | 75 | 0.37 | Why? |
| Diffusion Tensor Imaging | 2 | 2018 | 125 | 0.35 | Why? |
| Botulinum Toxins, Type A | 3 | 2019 | 134 | 0.34 | Why? |
| Brain Mapping | 4 | 2017 | 228 | 0.34 | Why? |
| Nervous System Diseases | 3 | 2020 | 4092 | 0.32 | Why? |
| Disability Evaluation | 3 | 2020 | 671 | 0.32 | Why? |
| Dementia | 3 | 2020 | 1861 | 0.28 | Why? |
| White Matter | 2 | 2018 | 369 | 0.28 | Why? |
| Diet | 1 | 2017 | 2052 | 0.27 | Why? |
| Alzheimer Disease | 2 | 2018 | 1020 | 0.27 | Why? |
| Cognition | 1 | 2012 | 1394 | 0.25 | Why? |
| Cognitive Dysfunction | 3 | 2019 | 1389 | 0.25 | Why? |
| Caregivers | 2 | 2017 | 3112 | 0.25 | Why? |
| Epilepsy | 3 | 2020 | 1401 | 0.25 | Why? |
| Gyrus Cinguli | 2 | 2018 | 28 | 0.24 | Why? |
| Translating | 2 | 2019 | 80 | 0.23 | Why? |
| Acetylcholine Release Inhibitors | 2 | 2017 | 32 | 0.22 | Why? |
| Polyradiculoneuropathy | 1 | 2020 | 32 | 0.21 | Why? |
| Sexuality | 2 | 2020 | 85 | 0.21 | Why? |
| Telemedicine | 9 | 2021 | 25032 | 0.21 | Why? |
| Gray Matter | 2 | 2018 | 150 | 0.21 | Why? |
| Diagnostic Imaging | 1 | 2008 | 1044 | 0.20 | Why? |
| Nociception | 1 | 2019 | 25 | 0.20 | Why? |
| CHARGE Syndrome | 1 | 2018 | 1 | 0.20 | Why? |
| Cortical Spreading Depression | 1 | 2018 | 5 | 0.19 | Why? |
| Amnesia | 1 | 2018 | 18 | 0.19 | Why? |
| Mental Processes | 1 | 2018 | 19 | 0.18 | Why? |
| Humans | 68 | 2021 | 930598 | 0.18 | Why? |
| Hyperalgesia | 1 | 2018 | 61 | 0.18 | Why? |
| Adaptation, Psychological | 1 | 2017 | 4996 | 0.18 | Why? |
| Nerve Fibers, Myelinated | 1 | 2017 | 11 | 0.18 | Why? |
| Trigeminal Autonomic Cephalalgias | 1 | 2017 | 1 | 0.18 | Why? |
| Imaging, Three-Dimensional | 3 | 2018 | 680 | 0.18 | Why? |
| Dura Mater | 1 | 2017 | 13 | 0.18 | Why? |
| Regression Analysis | 4 | 2018 | 2484 | 0.18 | Why? |
| Cognition Disorders | 3 | 2018 | 574 | 0.17 | Why? |
| Hydroxycholesterols | 1 | 2018 | 85 | 0.17 | Why? |
| Male | 41 | 2021 | 367725 | 0.17 | Why? |
| Hypertrophy | 1 | 2017 | 86 | 0.17 | Why? |
| Recommended Dietary Allowances | 1 | 2017 | 43 | 0.17 | Why? |
| Neuromuscular Diseases | 1 | 2021 | 303 | 0.17 | Why? |
| Stroke Rehabilitation | 1 | 2021 | 299 | 0.17 | Why? |
| Psychiatric Status Rating Scales | 3 | 2020 | 1340 | 0.16 | Why? |
| Vertigo | 1 | 2017 | 141 | 0.16 | Why? |
| Fatigue | 2 | 2018 | 2479 | 0.16 | Why? |
| Fatty Acids, Unsaturated | 1 | 2017 | 70 | 0.16 | Why? |
| Models, Neurological | 1 | 2017 | 121 | 0.16 | Why? |
| Middle Aged | 33 | 2021 | 270681 | 0.16 | Why? |
| Rest | 1 | 2017 | 188 | 0.16 | Why? |
| Work Performance | 1 | 2018 | 186 | 0.16 | Why? |
| Immunologic Factors | 4 | 2021 | 4206 | 0.16 | Why? |
| Random Allocation | 1 | 2019 | 773 | 0.16 | Why? |
| Image Processing, Computer-Assisted | 5 | 2018 | 1383 | 0.16 | Why? |
| Corpus Callosum | 1 | 2018 | 182 | 0.15 | Why? |
| Female | 40 | 2021 | 380317 | 0.15 | Why? |
| Pain Measurement | 1 | 2019 | 533 | 0.15 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 317 | 0.15 | Why? |
| Positron-Emission Tomography | 2 | 2018 | 802 | 0.15 | Why? |
| Leptin | 1 | 2017 | 141 | 0.15 | Why? |
| Fatty Acids | 1 | 2017 | 238 | 0.15 | Why? |
| Myasthenia Gravis | 1 | 2021 | 385 | 0.15 | Why? |
| Attention | 1 | 2018 | 335 | 0.14 | Why? |
| Italy | 16 | 2021 | 38444 | 0.14 | Why? |
| Adult | 29 | 2021 | 244371 | 0.14 | Why? |
| Neurologic Examination | 1 | 2017 | 428 | 0.14 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.13 | Why? |
| Azathioprine | 1 | 2014 | 161 | 0.13 | Why? |
| Glucose | 1 | 2018 | 573 | 0.13 | Why? |
| Complementary Therapies | 1 | 2017 | 280 | 0.13 | Why? |
| Stress, Psychological | 1 | 2017 | 10231 | 0.13 | Why? |
| Body Composition | 1 | 2017 | 414 | 0.13 | Why? |
| Rituximab | 1 | 2021 | 1096 | 0.12 | Why? |
| Walking | 1 | 2017 | 442 | 0.12 | Why? |
| Micronutrients | 1 | 2017 | 310 | 0.12 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.12 | Why? |
| Social Networking | 1 | 2018 | 737 | 0.11 | Why? |
| Interferons | 2 | 2021 | 2885 | 0.11 | Why? |
| Quality of Life | 5 | 2020 | 9820 | 0.11 | Why? |
| Internet | 3 | 2018 | 6204 | 0.11 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.11 | Why? |
| Osteoporosis | 1 | 2017 | 410 | 0.11 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.11 | Why? |
| Dysbiosis | 1 | 2017 | 685 | 0.11 | Why? |
| Neurodegenerative Diseases | 1 | 2017 | 469 | 0.11 | Why? |
| Sinus Thrombosis, Intracranial | 1 | 2017 | 550 | 0.11 | Why? |
| Neuroimaging | 1 | 2018 | 1106 | 0.11 | Why? |
| Continuity of Patient Care | 1 | 2020 | 1574 | 0.10 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.10 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.10 | Why? |
| Aged | 18 | 2021 | 215776 | 0.10 | Why? |
| Surveys and Questionnaires | 8 | 2021 | 43792 | 0.09 | Why? |
| Interferon-beta | 1 | 2014 | 979 | 0.09 | Why? |
| Anisotropy | 2 | 2017 | 56 | 0.09 | Why? |
| Critical Pathways | 1 | 2018 | 1587 | 0.09 | Why? |
| Atrophy | 2 | 2018 | 192 | 0.09 | Why? |
| Radionuclide Imaging | 1 | 2008 | 184 | 0.08 | Why? |
| Malnutrition | 1 | 2017 | 932 | 0.08 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.08 | Why? |
| Organ Size | 2 | 2018 | 384 | 0.08 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.08 | Why? |
| Sexual and Gender Minorities | 1 | 2017 | 1019 | 0.08 | Why? |
| Nutritional Status | 1 | 2017 | 1403 | 0.08 | Why? |
| Education, Medical, Graduate | 1 | 2021 | 2082 | 0.08 | Why? |
| Self Report | 1 | 2018 | 3802 | 0.08 | Why? |
| Anxiety Disorders | 1 | 2019 | 2290 | 0.08 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.07 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.07 | Why? |
| Resilience, Psychological | 1 | 2020 | 2329 | 0.07 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.07 | Why? |
| Cross-Sectional Studies | 5 | 2018 | 53120 | 0.07 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.07 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.06 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2019 | 10649 | 0.06 | Why? |
| Vitamin D | 1 | 2017 | 2904 | 0.06 | Why? |
| Dimethyl Fumarate | 1 | 2021 | 116 | 0.05 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.05 | Why? |
| Pandemics | 13 | 2021 | 389249 | 0.05 | Why? |
| Peripheral Nervous System | 1 | 2020 | 129 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.05 | Why? |
| Natalizumab | 1 | 2021 | 144 | 0.05 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.05 | Why? |
| Chronic Disease | 3 | 2019 | 5139 | 0.05 | Why? |
| Internship and Residency | 1 | 2021 | 4987 | 0.05 | Why? |
| Fingolimod Hydrochloride | 1 | 2021 | 217 | 0.05 | Why? |
| C9orf72 Protein | 1 | 2018 | 27 | 0.05 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.05 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.05 | Why? |
| Work Capacity Evaluation | 1 | 2018 | 33 | 0.05 | Why? |
| Putamen | 1 | 2018 | 24 | 0.05 | Why? |
| Multivariate Analysis | 2 | 2021 | 5440 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.05 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.04 | Why? |
| Disabled Persons | 2 | 2019 | 1152 | 0.04 | Why? |
| Functional Laterality | 1 | 2017 | 57 | 0.04 | Why? |
| Patient Education as Topic | 2 | 2017 | 1476 | 0.04 | Why? |
| Prescription Drug Overuse | 1 | 2017 | 59 | 0.04 | Why? |
| DNA Helicases | 1 | 2018 | 203 | 0.04 | Why? |
| Discriminant Analysis | 1 | 2017 | 170 | 0.04 | Why? |
| Stroke | 1 | 2021 | 8839 | 0.04 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.04 | Why? |
| Mental Recall | 1 | 2017 | 77 | 0.04 | Why? |
| Anxiety | 2 | 2020 | 17311 | 0.04 | Why? |
| Quarantine | 2 | 2020 | 18418 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Esters | 1 | 2018 | 300 | 0.04 | Why? |
| Age of Onset | 1 | 2017 | 557 | 0.04 | Why? |
| Social Media | 1 | 2017 | 5798 | 0.04 | Why? |
| DNA-Binding Proteins | 1 | 2018 | 469 | 0.04 | Why? |
| Executive Function | 1 | 2017 | 173 | 0.04 | Why? |
| Personality | 1 | 2019 | 277 | 0.04 | Why? |
| Decision Trees | 1 | 2017 | 441 | 0.04 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.04 | Why? |
| Practice Guidelines as Topic | 4 | 2020 | 15421 | 0.04 | Why? |
| Cerebrovascular Circulation | 1 | 2017 | 340 | 0.03 | Why? |
| Mood Disorders | 1 | 2018 | 431 | 0.03 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2021 | 1289 | 0.03 | Why? |
| Reference Values | 1 | 2017 | 795 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.03 | Why? |
| Multimodal Imaging | 1 | 2018 | 534 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.03 | Why? |
| Program Development | 1 | 2019 | 1089 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.03 | Why? |
| Social Behavior | 1 | 2020 | 882 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| Information Seeking Behavior | 1 | 2018 | 539 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Wearable Electronic Devices | 1 | 2018 | 694 | 0.03 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.03 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.03 | Why? |
| Personal Satisfaction | 1 | 2020 | 1243 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Single-Blind Method | 1 | 2014 | 1283 | 0.03 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.03 | Why? |
| Hot Temperature | 1 | 2017 | 1299 | 0.02 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Smartphone | 1 | 2020 | 1840 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Health Surveys | 1 | 2019 | 2841 | 0.02 | Why? |
| Animals | 1 | 2017 | 78931 | 0.02 | Why? |
| Health Communication | 1 | 2018 | 1120 | 0.02 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Depression | 2 | 2020 | 14116 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| France | 1 | 2021 | 12074 | 0.02 | Why? |
| Recurrence | 1 | 2014 | 3675 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Occupational Stress | 1 | 2018 | 2044 | 0.02 | Why? |
| Oxygen | 1 | 2017 | 3715 | 0.02 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Attitude to Health | 1 | 2017 | 2002 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Sex Factors | 1 | 2019 | 11014 | 0.01 | Why? |
| Triage | 1 | 2020 | 7151 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Spain | 1 | 2017 | 15545 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Mass Screening | 1 | 2019 | 8005 | 0.01 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2019 | 22971 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2014 | 17020 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.01 | Why? |